Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant: We’ll Bump Allergan Offer to $200 a Share

By Drug Discovery Trends Editor | October 27, 2014

The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12%, which would mean $200 or more per share for the maker of Botox.
 
The letter to Allergan’s board did not break down the exact terms of the new offer, but Valeant said the increase would consist of added “consideration” and expected appreciation of Valeant’s own stock to be used in any deal.
 
Allergan did not immediately respond to a request for comment.
 
The letter was released publicly just before Allergan released its third-quarter earnings, which topped Wall Street expectations.
 
Valeant, based in Laval, Quebec, has made several offers to buy Allergan, only recently offering about $179 per share at current stock values.
 
Allergan, which is based in Irvine, California, has set a Dec. 18 date for a special shareholder meeting at which its shareholders will consider replacing most of its board.
 
That could give Valeant and activist investor Bill Ackman’s Pershing Square Capital Management LP, which has built a large stake in Allergan, a chance at a takeover. Beyond control of the board, there also will be a vote on whether Allergan should talk to Valeant Pharmaceuticals International Inc. and Pershing Square.
 
The companies have traded barbs throughout the takeover battle, and Valeant has said that Allergen has made misleading statements about Valeant’s businesses, including Bausch + Lomb, which Valeant acquired last year.
 
Allergan’s third quarter was helped by rising drug and medical device sales.
 
Allergan on Monday reported net income of $312.5 million, or $1.03 per share, in its third quarter, which ended Sept. 30. That’s up from $300.8 million, or $1 per share, in the same quarter last year
 
Earnings, adjusted for one-time gains and costs, were $1.78 per share. Analysts surveyed by Zacks Investment Research expected $1.62 per share, on average.
 
The company, which also makes eyelash extender Latisse and dry-eye drug Restasis, posted revenue of $1.82 billion in the period, which also beat Street forecasts. Analysts expected $1.77 billion, according to Zacks.
 
Shares of Allergan Inc. rose $5.59, or 3%, to $189.80 in premarket trading.
 
Date: October 27, 2014
Source: The Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE